Fulcrum Therapeutics (NASDAQ:FULC) Upgraded to Buy at HC Wainwright

Key Points

• Fulcrum Therapeutics received an upgrade from HC Wainwright, moving from a "neutral" to a "buy" rating, with a new target price of $12.00, indicating a potential upside of 55.26% from its current price.
• In addition to HC Wainwright, several other analysts have also upgraded Fulcrum Therapeutics, with Cantor Fitzgerald setting a price target of $10.00 and Piper Sandler raising their target to $9.00.
• Fulcrum Therapeutics' stock is currently trading at $7.73, down 1% during midday trading, and the company reported earnings of ($0.28) per share, surpassing analyst expectations.

HC Wainwright upgraded shares of Fulcrum Therapeutics (NASDAQ:FULC - Free Report) from a neutral rating to a buy rating in a research report released on Tuesday morning, Marketbeat Ratings reports. They currently have $12.00 target price on the stock, up from their previous target price of $4.00. HC Wainwright also issued estimates for Fulcrum Therapeutics' Q3 2025 earnings at ($0.26) EPS, Q4 2025 earnings at ($0.28) EPS, FY2025 earnings at ($1.10) EPS, FY2026 earnings at ($1.27) EPS, FY2027 earnings at ($1.26) EPS, FY2028 earnings at ($0.96) EPS and FY2029 earnings at ($0.65) EPS.

Several other analysts also recently weighed in on the company. Piper Sandler reiterated an "overweight" rating and issued a $9.00 price objective (up previously from $6.00) on shares of Fulcrum Therapeutics in a research report on Thursday, May 29th. Leerink Partnrs raised Fulcrum Therapeutics from a "hold" rating to a "strong-buy" rating in a research note on Friday, May 23rd. Cantor Fitzgerald raised Fulcrum Therapeutics from a "neutral" rating to an "overweight" rating and set a $10.00 target price on the stock in a research note on Thursday, May 15th. Finally, Leerink Partners raised Fulcrum Therapeutics from a "market perform" rating to an "outperform" rating and boosted their target price for the company from $4.00 to $12.00 in a research note on Friday, May 23rd. One research analyst has rated the stock with a sell rating, two have assigned a hold rating, four have given a buy rating and one has issued a strong buy rating to the company's stock. According to data from MarketBeat, the company has a consensus rating of "Moderate Buy" and a consensus price target of $7.57.

Fulcrum Therapeutics Trading Up 2.0%

FULC stock traded up $0.13 during midday trading on Tuesday, hitting $6.86. The company had a trading volume of 138,336 shares, compared to its average volume of 583,811. Fulcrum Therapeutics has a 52 week low of $2.32 and a 52 week high of $10.13. The stock's 50 day moving average price is $7.16 and its 200 day moving average price is $4.97. The stock has a market cap of $370.51 million, a price-to-earnings ratio of -5.61 and a beta of 2.37.

Fulcrum Therapeutics (NASDAQ:FULC - Get Free Report) last announced its quarterly earnings data on Tuesday, July 29th. The company reported ($0.28) earnings per share for the quarter, beating the consensus estimate of ($0.29) by $0.01. Analysts predict that Fulcrum Therapeutics will post -0.16 earnings per share for the current year.

Hedge Funds Weigh In On Fulcrum Therapeutics

Several hedge funds have recently made changes to their positions in FULC. Jump Financial LLC purchased a new stake in Fulcrum Therapeutics in the first quarter worth $30,000. Brooklyn Investment Group grew its stake in Fulcrum Therapeutics by 209.7% in the first quarter. Brooklyn Investment Group now owns 12,190 shares of the company's stock worth $35,000 after purchasing an additional 8,254 shares during the period. BNP Paribas Financial Markets purchased a new stake in Fulcrum Therapeutics in the fourth quarter worth $38,000. Virtu Financial LLC purchased a new stake in Fulcrum Therapeutics in the first quarter worth $39,000. Finally, Mariner LLC purchased a new stake in Fulcrum Therapeutics in the fourth quarter worth $78,000. 89.83% of the stock is owned by hedge funds and other institutional investors.

About Fulcrum Therapeutics

Fulcrum Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its product candidates are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy is under phase III clinical trial; and pociredir, a fetal hemoglobin inducer for the treatment of sickle cell disease and beta-thalassemia is under phase I clinical trial.